Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist

Bioorg Med Chem Lett. 2009 Jan 1;19(1):209-13. doi: 10.1016/j.bmcl.2008.10.115. Epub 2008 Oct 31.

Abstract

Replacement of the cyclic carbamate in our previously disclosed 1-oxa-3,9-diazaspiro[5.5]undecan-2-one template led to the discovery of two novel series of 3,9-diazaspiro[5.5]undecane and undeca-2-one CCR5 antagonists. The synthesis, SAR, and antiviral activities of these two series are described. One compound (32) was found to have attractive combination of antiviral potency, selectivity, and pharmacokinetic profile. The asymmetric synthesis of 32 was also accomplished and both enantiomers were equally potent.

MeSH terms

  • Administration, Oral
  • Alkanes / chemical synthesis*
  • Alkanes / pharmacology
  • Animals
  • Antiviral Agents / chemical synthesis*
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / pharmacology
  • Biological Availability
  • CCR5 Receptor Antagonists*
  • Drug Discovery
  • Spiro Compounds / chemical synthesis*
  • Spiro Compounds / pharmacology
  • Structure-Activity Relationship

Substances

  • Alkanes
  • Antiviral Agents
  • CCR5 Receptor Antagonists
  • Spiro Compounds
  • undecane